Tachykinin receptor antagonists in clinical trials

Bibliography

• Duffy RA. Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs 2004;9:9-21
   PubMedGoogle Scholar
• Leslie RA. Neuractive substances in the dorsal vagal complex and medulla oblongata: nucleus of the tractus solitarius, area postrema and dorsal mptor vagal nucleus. Neurochem Int 1985;7:191-211
   PubMed Web of Science ®Google Scholar
• Kramer MS, Cutler N, Feighner J, Distinct mechanism for antidepressant activity by blockade of central Substance P receptors. Science 1998;281:1640-5
   PubMed Web of Science ®Google Scholar
• Hill R. NK1 (substance P) receptor antagonists: why are they not analgesic in humans? Trends Pharmacol Sci 2000;21:244-6
   PubMed Web of Science ®Google Scholar
• Urban LA, Fox AJ. NK1 receptor antagonists – are they really without effect in the pain clinic? Trends Pharmacol Sci 2000;21:462-4
   PubMed Web of Science ®Google Scholar
• Rupniak NM, Kramer MS. Discovery of the anti-depressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. TiPS 1999;20:485-90
   PubMed Web of Science ®Google Scholar
• Kramer MS, Winokur A, Kelsey J, Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004;29:385-92
   PubMed Web of Science ®Google Scholar
• Holmes A, Heilig M, Rupniak MJ, Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 2003;24:580-8
   PubMed Web of Science ®Google Scholar
• Merck discontinues development of MK-0869 for depression. Merck & Co, Inc. (November 2003) Press Release
   Google Scholar
• Millan M. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370
   PubMed Web of Science ®Google Scholar
• Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005;4:1-8
   Web of Science ®Google Scholar
• Lucot JB, Obach RS, McLean S, Watson JW. Effect of CP-99,994 on the responses to provocative motion in the cat. Br J Pharmacol 1997;120:116-20
   PubMed Web of Science ®Google Scholar
• Reid K, Sciberras DG, Gertz BJ, Comparison of a neurokinin-1 antagonist, L-758,298, and scopolamine with placebo in the prevention of motion-induced nausea in man. Br J Clin Pharmacol 1998;46:282P
   Google Scholar
• Reid K, Palmer JL, Wright RJ, Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. Br J Clin Pharmacol 2000;50:61-4
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Osoba D, Kris MG, Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999;17:2971-94
   PubMed Web of Science ®Google Scholar
• Navari RM. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and antinausea activities. Curr Opinion Invest Drugs 2008;9:774-85
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Van Belle S, Aapro M, Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003;39:1074-80
   PubMed Web of Science ®Google Scholar
• Tattersall FD, Rycroft W, Cumberbatch M, The novel NK1 receptor antagonist aprepitant (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacol 2000;39:652-63
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-9
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8
   PubMed Web of Science ®Google Scholar
• Gralla RJ, de Wit R, Herrstedt J, Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer 2005;104:864-8
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Herrstedt J, Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006;14:354-60
   PubMed Web of Science ®Google Scholar
• de Wit R, Herrstedt J, Rapoport B, Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-11
   PubMed Web of Science ®Google Scholar
• Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 2008;112(9):2080-7
   PubMed Web of Science ®Google Scholar
• Gore L, Chawla S, Petrilli A, Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009;52:242-7
   PubMed Web of Science ®Google Scholar
• Warr DG, Hesketh PJ, Gralla RJ, Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:5851
   Web of Science ®Google Scholar
• Herrstedt J, Muss HB, Warr DG, Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104(7):1548-55
   PubMed Web of Science ®Google Scholar
• Hesketh P, Younger J, Sanz-Altamira P, Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer 2009;17:1065-70
   PubMed Web of Science ®Google Scholar
• Jordan K, Kinitz I, Voigt W, Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 2009;45:1184-7
   PubMed Web of Science ®Google Scholar
• Moore S, Tumeh J, Wojtanowski S, Flowers C. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health 2007;10(1):23-31
   PubMed Web of Science ®Google Scholar
• Lordick F, Ehlken B, Ihbe-Heffinger A, Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer 2007;43:299-307
   PubMed Web of Science ®Google Scholar
• Annemans L, Strens D, Lox E, Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer 2008;16:905-15
   PubMed Web of Science ®Google Scholar
• EMEND (aprepitant), an antiemetic aimed at preventing nausea and vomiting in patients undergoing chemotherapy, is now reimbursed in Quebec Merck Frosst Canada & Co Press Release, 2008:December 05
   Google Scholar
• Olver IN. Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Ther Clin Risk Manag 2008;4:501-6
   PubMedGoogle Scholar
• McCrea JB, Majumdar AK, Goldberg MR, Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74:17-24
   PubMed Web of Science ®Google Scholar
• Blum RA, Majumdar A, McCrea J, Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25:1407-19
   PubMed Web of Science ®Google Scholar
• FDA site, Aprepitant label version February 2009. Available from http://www.fda.gov. [Last accessed February 2009]
   Google Scholar
• Depre M, Van Hecken A, Oeyen M, Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005;62:341-6
   Google Scholar
• Navari R. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and antinausea activities. Curr Opin Invest Drugs 2008;9:774-85
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Grunberg S, Rolski J, Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC). J Clin Oncol 2008;26: abstract 9549
   Web of Science ®Google Scholar
• Strausz J, Rolski J, Aziz Z, Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day iv/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC). J Clin Oncol 2008;26: abstract 20585
   Web of Science ®Google Scholar
• Grunberg SM, Rolski J, Strauz J, Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:549-58
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Aziz Z, Shaharyar A, Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol 2008;26: abstract 9540
   Web of Science ®Google Scholar
• Aziz Z, Arpornwirat W, Herrstedt J, A Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day iv/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol 2008;26: abstract 20512
   Web of Science ®Google Scholar
• A study of IV casopitant for the prevention of chemotherapy induced nausea and vomiting. Available from: www.clinicaltrials.gov study NCT00601172. [Last accessed February 2009]
   Google Scholar
• Blum R, Adams LM, Johnson BM, Effect of casopitant, a novel neurokinin-1 (NK-1) receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV), on the pharmacokinetics (PK) and pharmacodynamics (PD) of steady-state warfarin. J Clin Oncol 2008;26: abstract 20587
   Web of Science ®Google Scholar
• Johnson B, Adams L, Lu E, Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer 2009;17:1177-85
   PubMed Web of Science ®Google Scholar
• Adams LM, Johnson B, Zhang K, Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. Support Care Cancer 2009;17:1187-93
   PubMed Web of Science ®Google Scholar
• GSK press release, 28 September 2009
   Google Scholar
• A multicenter, randomized, controlled trial of SCH 619734 for the treatment of chemotherapy-induced nausea and vomiting (study P04351AM2). Available from: www.clinicaltrials.gov study NCT00394966. [Last accessed February 2009]
   Google Scholar
• Wilhelm SM, Dehoorne-Smith ML, Kale-Bradhan PB. Prevention of postoperative nausea and vomiting. Ann Pharmacother 2007;41:68-78
   PubMed Web of Science ®Google Scholar
• Casopitant and ZOFRAN to prevent post operative nausea and vomiting in women. Available from: www.clinicaltrials.gov study NCT00334152. [Last accessed February 2009]
   Google Scholar
• Casopitant (oral) and ZOFRAN to prevent postoperative nausea and vomiting in women. Available from: www.clinicaltrials.gov study NCT00326248. [Last accessed February 2009]
   Google Scholar
• A randomized controlled study of rolapitant for the prevention of nausea and vomiting following surgery (study P04937AM1). Available from: www.clinicaltrials.gov study NCT00539721. [Last accessed February 2009]
   Google Scholar
• Two randomised, double-blind, placebo-controlled studies have been carried out in subjects with major depressive disorder (Nct00880048 and NCT00880399). Available from: www.clinicaltrials.gov studies NCT00880399 and NCT00880048. [Last accessed February 2009]
   Google Scholar
• IDdb Meeting Report. Medicinal and Bioorganic Chemistry Foundation – Ninth Winter Conference, Steamboat Springs Resort, CO, USA, January 25-29, 2009
   Google Scholar
• Furmark T, Appel L, Michelgaard A, Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram or placebo. Biol Psychiatry 2005;58:132-42
   PubMed Web of Science ®Google Scholar
• A combination therapy in patients with social anxiety disorder. Available from: www.clinicaltrials.gov study NTC00403962. [Last accessed February 2009]
   Google Scholar
• Various studies on GW679769 (Nct00650871, Nct00280423, Nct00280436 and Nct00354809). Available from: www.clinicaltrials.gov studies NCT00650871, NCT00280423, NCT00280436, NCT00354809. [Last accessed February 2009]
   Google Scholar
• A study with GW597599 and GR205171: potential new drugs for the treatment of primary insomnia. Available from: www.clinicaltrials.gov study NCT00606697. [Last accessed February 2009]
   Google Scholar
• Substance P antagonist in the treatment of posttraumatic stress disorder. Available from: www.clinicaltrials.gov study NCT00383786. [Last accessed February 2009]
   Google Scholar
• Effectiveness of an NK1 antagonist in decreasing symptoms of post-traumatic stress disorder. Available from: www.clinicaltrials.gov study NCT00211861. [Last accessed February 2009]
   Google Scholar
• George DT, Gilman J, Hersh J, Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 2008;319:1536-9
   PubMed Web of Science ®Google Scholar
• Ripley TL, Gadd CA, De Felipe C, Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors. Neuropharmacology 2002;43:1258-68
   PubMed Web of Science ®Google Scholar
• A study in the treatment of alcohol dependence. Available from: www.clinicaltrial.gov, NCT00805441
   Google Scholar
• Phase IIA study in patients with schizophrenia. Available from: www.clinicaltrials.gov NCT00686998. [Last accessed February 2009]
   Google Scholar
• NCT00428519: Effects of Treatment With Aprepitant (Emend) in HIV Infected Individuals University of Pennsylvania. Available from: www.clinicaltrials.gov, 2008. [Last accessed February 2009]
   Google Scholar
• Wang J, Douglas SD, Song L, Neurokinin-1 receptor antagonist (aprepitant) suppresses hiv-1 infection of microglia/macrophages. Neuroimmune Pharmacol 2008;3:257-64
   PubMed Web of Science ®Google Scholar
• GW679769 in fibromyalgia. Available from: www.clinicaltrials.gov study NCT00264628. [Last accessed February 2009]
   Google Scholar
• Patacchini R, Maggi CA. Peripheral tachykinin receptors as target for new drugs. Eur J Pharmacol 2001;429:13-21
   PubMed Web of Science ®Google Scholar
• Effects of GW679769 on bladder nerve function and symptoms of overactive bladder in spinal cord injury patients. Available from: www.clinicaltrials.gov study NCT00332319. [Last accessed February 2009]
   Google Scholar
• A study of GW679769 compared to placebo in women with overactive bladder. Available from: www.clinicaltrials.gov study NCT00321477. [Last accessed February 2009]
   Google Scholar
• MILADY: a randomized, placebo-controlled safety and efficacy trial of SSR240600C in treatment of overactive bladder or urge urinary incontinence. Available from: www.clinicaltrials.gov study NCT00174798. [Last accessed February 2009]
   Google Scholar
• SSR240600C treatment in women with overactive bladder. Available from: www.clinicaltrials.gov study NCT00564226. [Last accessed February 2009]
   Google Scholar
• Bardia A, Thompson S, Atherton P, Pilot evaluation of aprepitant for the treatment of hot flashes. Supportive Cancer Ther 2006;3:240-6
   PubMedGoogle Scholar
• Shimizu Y, Matsuyama H, Shiina T, Tachykinin and their functions in the gastrointestinal tract. Cell Mol Life Sci 2008;65:295-311
   PubMed Web of Science ®Google Scholar
• Evangelista S, Patacchini R, Maggi CA. Role of peripheral tachykinin receptors in neurogenic inflammation of the respiratory, genitourinary and gastrointestinal systems. Curr Med Chem Anti Inflamm Anti Allergy Agents 2003;2:157-74
   Google Scholar
• Bensaid M, Faucheux BA, Hirsch E, Expression of tachykinin NK2 receptor mRNA in human brain. Neurosci Lett 2001;303:25-8
   PubMed Web of Science ®Google Scholar
• Saffroy M, Torrens Y, Glowinski J, Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience 2003;116:761-73
   PubMed Web of Science ®Google Scholar
• Walsh DM, Stratton SC, Harvey FJ, The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology 1995;121:186-91
   PubMed Web of Science ®Google Scholar
• Albert JS. Neurokinin antagonists and their potential role in treating depression and other stress disorders. Expert Opin Ther Pat 2004;14:1421-33
   Web of Science ®Google Scholar
• Boutaghou-Cherid H, Porcher C, Liberge M, Expression of the neurokinin type 1 receptor in the human colon. Autonom Neurosci 2006;124:9-17
   PubMed Web of Science ®Google Scholar
• Jaafari N, Khomitch-Baud A, Christen M-O, Distribution pattern of tachykinin NK2 receptors in human colon: involvement in the regulation of intestinal motility. J Comp Neurol 2007;503:381-91
   PubMed Web of Science ®Google Scholar
• Lordal M, Navalesi G, Theodorsson E, A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br J Pharmacol 2001;134:215-23
   PubMed Web of Science ®Google Scholar
• Bai TR, Zhou D, Weir T, Substance P (NK1)- and neurokinin A (NK2)-receptor gene expression in inflammatory airway disease. Am J Physiol 1995;269:L309-17
   PubMed Web of Science ®Google Scholar
• Steinberg R, Alonso R, Griebel G, Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 2001;299:449-58
   PubMed Web of Science ®Google Scholar
• Louis C, Stemmelin J, Boulay D, Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol Biochem Behav 2008;89:36-45
   PubMed Web of Science ®Google Scholar
• Le Fur G. In: Sanofi-Synthélabo Information Meeting, February 16, 2004. p. 53-6
   Google Scholar
• Clinical trials reported in the ClinicalTrials.gov database; Available from: http://www.clinicaltrials.gov/ [Accessed on 26 August 2008]
   Google Scholar
• Cluzel M. Research and development. In: Sanofi Aventis Information Meeting, February 13, 2007. p. 119-23. Available from: http://www.sanofi-aventis.com [Last accessed on 26 February 2007]
   Google Scholar
• Clyburn F, Schwabe S. Central Nervous System. In: Sanofi Aventis R&D Meeting, September 17, 2007, p. 93-6. Available from: http://www.sanofi-aventis.com [Last accessed on 3 October 2007]
   Google Scholar
• Sanofi Aventis Press Release, April 30, 2008. p. 10
   Google Scholar
• Sanofi Aventis Press Release, July 31, 2008. p. 13
   Google Scholar
• Sanofi Aventis Press Release, April 29, 2009. p. 8
   Google Scholar
• Lecci A, Capriati A, Altamura M, Maggi CA. Tachykinin and tachykinin receptors in the gut, with special reference to NK2 receptors in human. Auton Neurosci 2006;126(7):232-49
   PubMedGoogle Scholar
• Catalioto RM, Criscuoli M, Cucchi P, MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist. Br J Pharmacol 1998;123:81-91
   PubMed Web of Science ®Google Scholar
• Toulouse M, Coelho AM, Fioramonti J, Role of tachykinin NK2 receptors in normal and altered rectal sensitivity in rats. Br J Pharmacol 2000;129:193-9
   PubMed Web of Science ®Google Scholar
• Laird JMA, Olivar T, Lopez-Garcia JA, Response of the rat spinal neurons to distension of inflamed colon: role of tachykinin NK2 receptors. Neuropharmacology 2001;40:696-701
   PubMed Web of Science ®Google Scholar
• Toulouse M, Fioramonti J, Maggi CA, Role of NK2 receptors in gastric barosensitivity and in experimental ileus in rats. Neurogastroenterol Motil 2001;13:45-53
   PubMed Web of Science ®Google Scholar
• Lecci A, Altamura M, Capriati A, Tachykinin receptors and gastrointestinal motility: focus on humans. Eur Rev Med Pharmacol Sci 2008;12:69-80
   PubMed Web of Science ®Google Scholar
• Cialdai C, Tramontana M, Patacchini R, MEN 15596, a novel nonpeptide tachykinin NK2 receptor antagonist. Eur J Pharmacol 2006;549:140-8
   PubMed Web of Science ®Google Scholar
• Giuliani S, Altamura M, Maggi CA. Ibodutant: tachykinin NK2 receptor antagonist. Treatment of irritable bowel syndrome. Drugs Fut 2008;33:111-5
   Web of Science ®Google Scholar
• Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of a 4-Week Treatment With Oral Doses of MEN15596 in Irritable Bowel Syndrome. ClinicalTrials.gov Identifier: NCT00761007. Available from: http://www.clinicaltrials.gov/. [Accessed on 30 September 2008]
   Google Scholar
• Efficacy, safety and tolerability of DNK-333 (25 and 100 mg bid) in women with diarrhea-predominant irritable bowel syndrome (IBS-D) (CDNK333B2201). ClinicalTrials.gov Identifier: NCT00699166. Available from: http://www.clinicaltrials.gov/. [Accessed on 28 August 2008]
   Google Scholar
• Efficacy and Safety of DNK333 in Women With Diarrhea-Predominant Irritable Bowel Syndrome (CDNK333B2201). ClinicalTrials.gov Identifier: NCT00394173. Available from: http://www.clinicaltrials.gov/. [Accessed on 28 August 2008]
   Google Scholar
• Altamura M, Manzini S, Lecci A. Tachykinin receptors in chronic inflammatory lower airway diseases. Expert Opin Ther Pat 2007;17:1241-73
   Web of Science ®Google Scholar
• Van Schoor J, Joos GF, Chasson BL, The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur Respir J 1998;12:17-23
   PubMed Web of Science ®Google Scholar
• Joos G, Schelfhout V, Van De Velde V, The effect of the tachykinin NK2 receptor antagonist MEN 11420 (nepadutant) on neurokinin A-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 2001;163:A628
   Google Scholar
• Joos GF, Vincken W, Louis R, Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J 2004;23:76-81
   PubMed Web of Science ®Google Scholar
• Diamant Z, De Haas S, Cohen J, Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma. Eur Respir J 2004;24:P1384
   Google Scholar
• Schelfhout V, Louis R, Lenz W, The triple neurokinin receptor antagonist CS-003 inhibits neurokinin A-induced bronchoconstriction in patients with asthma. Pulm Pharmacol Ther 2006;19:413-8
   PubMed Web of Science ®Google Scholar
• Kraan J, Vink-Klooster H, Postma DS. The NK-2 receptor antagonist SR 48968C does not improve adenosine hyperresponsiveness and airway obstruction in allergic asthma. Clin Exp Allergy 2001;31:274-8
   PubMed Web of Science ®Google Scholar
• Boot JD, de Haas S, Tarasevych S, Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med 2007;175:450-7
   PubMed Web of Science ®Google Scholar
• Almeida TA, Rojo J, Nieto PM, Tachykinin and tachykinin receptors: structure and activity relationships. Curr Med Chem 2004;11:2045-81
   PubMed Web of Science ®Google Scholar
• Rigby M, O'Donnell R, Rupniak NM. Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. J Comp Neurol 2005;490:335-53
   PubMed Web of Science ®Google Scholar
• Langlois X, Wintmolders C, Te Riele P, Detailed distribution of neurokinin 3 receptors in the rat, guinea-pig and gerbil brain: a comparative autoradiographic study. Neuropharmacology 2001;40:242-53
   PubMed Web of Science ®Google Scholar
• Maggi CA, Patacchini R, Rovero P, Tachykinin receptors and tachykinin receptor antagonists. J Aut Pharmacol 1993;13:23-93
   PubMedGoogle Scholar
• Marco N, Thirion A, Mons G, Activation of dopaminergic and cholinergic neurotrasmission by tachykinin NK3 receptor stimulation: An in vivo microdialysis approach in guinea-pig. Neuropeptides 1998;161:975-84
   Google Scholar
• Stoessl AJ, Szczutkowski E, Glenn B, Behavioral effects of selective tachykinin agonists in midbrain dopamine regions. Brain Res 1991;565:254-62
   PubMed Web of Science ®Google Scholar
• Spooren W, Riemer C, Meltzer H. NK3 receptor antagonists: the next generation of antipsychotics? Nature 2005;4:967-75
   Web of Science ®Google Scholar
• Dawson LA, Cato KJ, Scott C, In vitro and in vivo characterization of the non-peptide nk(3) receptor antagonist sb-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology 2007;33:1642-52
   PubMed Web of Science ®Google Scholar
• Sarau HM, Griswold DE, Potts W, Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther 1997;281:1303-11
   PubMed Web of Science ®Google Scholar
• Tian G, Wilkins D, Scott CW. Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition. Mol Pharmacol 2007;71:902-11
   PubMed Web of Science ®Google Scholar
• Couture R, Toma N, Barbot L. SR142801 behaves as a tachykinin NK-3 receptor agonist on a spinal nociceptive reflex in the rat. Life Sci 2000;66:51-65
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Arvanitis L, Bauer D, A placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorders. Am J Psychiat 2004;161:975-84
   PubMed Web of Science ®Google Scholar
• Emonds-Alt X, Proietto V, Steinberg R, Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Can J Physiol Pharmacol 2002;80:482-8
   PubMed Web of Science ®Google Scholar
• Press release from Sanofi-Aventis, 31 August 2005
   Google Scholar
• Sanofi-Aventis Informatin meeting, 12 February 2008
   Google Scholar
• GSK R&D Day 2003. Psychiatry update
   Google Scholar
• GSK R&D Day 2004. Psychiatry update
   Google Scholar
• Available from: http://www.clinicaltrials.gov study NCT00103727
   Google Scholar
• Kronenberg G, Berger P, Tauber RF, Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry 2005;38:24-9
   PubMed Web of Science ®Google Scholar
• LeFur G. In: Sanofi-Aventis inormation meeting, 18 December 2003. p. 35
   Google Scholar
• Sanger GJ, Tuladhar BR, Bueno L, Defensive and pathological functions of the gastrointestinal NK3 receptor. Vasc Pharmacol 2006;45:215-20
   PubMed Web of Science ®Google Scholar
• Houghton LA, Cremonini F, Camilleri M, Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil 2007;19:732-43
   PubMed Web of Science ®Google Scholar
• Dukes GE, Dewit OE, Sanger GJ, Lack of effect of the NK3 receptor antagonist, talnetant SB223242 on symptoms of IBS: results of 2 randomized, double-blind, placebo-controlled dose ranging trials. Gastroenterology 2007;132(Suppl 1):A60
   Google Scholar
• Thompson WG, Longstreth GF, Drossman DA, Functional bowel disorders and functional abdominal pain. Gut 1999;45(Suppl 2):1143-7
   Google Scholar